The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Doxil® — The first FDA-approved nano-drug: Lessons learned
Barenholz, Y. (. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.03.020 · Cited by 4,792
Diffusion of univalent ions across the lamellae of swollen phospholipids
Bangham, A. D., Standish, M. M., & Watkins, J. C. (1965) · Journal of Molecular Biology · doi:10.1016/s0022-2836(65)80093-6 · Cited by 4,664
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives
Knop, K., Hoogenboom, R., Fischer, D., & Schubert, U. S. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200902672 · Cited by 3,533
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Biodegradable Long-Circulating Polymeric Nanospheres
Gref, R., Minamitake, Y., Peracchia, M. T., Trubetskoy, V., Torchilin, V., & Langer, R. (1994) · Science · doi:10.1126/science.8128245 · Cited by 2,920
Cited by
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.09.012 · Cited by 4,523
Bertrand, N., Wu, J., Xu, X., Kamaly, N., & Farokhzad, O. C. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.11.009 · Cited by 2,824
Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications
Wicki, A., Witzigmann, D., Balasubramanian, V., & Huwyler, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.030 · Cited by 1,901
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
Hare, J. I., Lammers, T., Ashford, M. B., Puri, S., Storm, G., & Barry, S. T. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.025 · Cited by 1,214
Self-citationHua, S., de Matos, M. B. C., Metselaar, J. M., & Storm, G. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00790 · Cited by 1,048
Self-citationInsight into nanoparticle cellular uptake and intracellular targeting
Yameen, B., Choi, W. I., Vilos, C., Swami, A., Shi, J., & Farokhzad, O. C. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.038 · Cited by 787
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come
Yingchoncharoen, P., Kalinowski, D. S., & Richardson, D. R. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012070 · Cited by 744
Principles in the design of ligand-targeted cancer therapeutics and imaging agents
Srinivasarao, M., Galliford, C. V., & Low, P. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4519 · Cited by 671
PEGylated and targeted extracellular vesicles display enhanced cell specificity and circulation time
Kooijmans, S. A. A., Fliervoet, L. A. L., van der Meel, R., Fens, M. H. A. M., Heijnen, H. F. G., van Bergen en Henegouwen, P. M. P., Vader, P., & Schiffelers, R. M. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.01.009 · Cited by 625
Self-citationExtracellular vesicles as drug delivery systems: Lessons from the liposome field
van der Meel, R., Fens, M. H. A. M., Vader, P., van Solinge, W. W., Eniola-Adefeso, O., & Schiffelers, R. M. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.07.049 · Cited by 482
Self-citationSurface-Engineered Dendrimers in Gene Delivery
Yang, J., Zhang, Q., Chang, H., & Cheng, Y. (2015) · Chemical Reviews · doi:10.1021/cr500542t · Cited by 429
Recent progress in development of siRNA delivery vehicles for cancer therapy
Kim, H. J., Kim, A., Miyata, K., & Kataoka, K. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.06.011 · Cited by 424
Smart drug delivery systems: from fundamentals to the clinic
Alvarez-Lorenzo, C., & Concheiro, A. (2014) · Chem. Commun. · doi:10.1039/c4cc01429d · Cited by 415
New Modalities for Challenging Targets in Drug Discovery
Valeur, E., Guéret, S. M., Adihou, H., Gopalakrishnan, R., Lemurell, M., Waldmann, H., Grossmann, T. N., & Plowright, A. T. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201611914 · Cited by 382
Nanomedicine of synergistic drug combinations for cancer therapy – Strategies and perspectives
Zhang, R. X., Wong, H. L., Xue, H. Y., Eoh, J. Y., & Wu, X. Y. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.06.012 · Cited by 380
Ramasamy, T., Ruttala, H. B., Gupta, B., Poudel, B. K., Choi, H.-G., Yong, C. S., & Kim, J. O. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.04.043 · Cited by 373
Zhang, R., Qin, X., Kong, F., Chen, P., & Pan, G. (2019) · Drug Delivery · doi:10.1080/10717544.2019.1582730 · Cited by 363
Targeting iron metabolism in drug discovery and delivery
Crielaard, B. J., Lammers, T., & Rivella, S. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.248 · Cited by 352
Advancement of the emerging field of RNA nanotechnology
Jasinski, D., Haque, F., Binzel, D. W., & Guo, P. (2017) · ACS Nano · doi:10.1021/acsnano.6b05737 · Cited by 352
Extracellular Vesicles: Potential Roles in Regenerative Medicine
De Jong, O. G., Van Balkom, B. W. M., Schiffelers, R. M., Bouten, C. V. C., & Verhaar, M. C. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00608 · Cited by 351
Chen, S., Zhong, Y., Fan, W., Xiang, J., Wang, G., Zhou, Q., Wang, J., Geng, Y., Sun, R., Zhang, Z., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00701-4 · Cited by 325
Lipid-Based DNA Therapeutics: Hallmarks of Non-Viral Gene Delivery
Buck, J., Grossen, P., Cullis, P. R., Huwyler, J., & Witzigmann, D. (2019) · ACS Nano · doi:10.1021/acsnano.8b07858 · Cited by 312
Transferrin Receptor-Mediated Endocytosis: A Useful Target for Cancer Therapy
Tortorella, S., & Karagiannis, T. C. (2014) · The Journal of Membrane Biology · doi:10.1007/s00232-014-9637-0 · Cited by 312
Antibody fragments as nanoparticle targeting ligands: a step in the right direction
Richards, D. A., Maruani, A., & Chudasama, V. (2017) · Chemical Science · doi:10.1039/c6sc02403c · Cited by 294
Belfiore, L., Saunders, D. N., Ranson, M., Thurecht, K. J., Storm, G., & Vine, K. L. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.02.040 · Cited by 294
Self-citationTargeting strategies for superparamagnetic iron oxide nanoparticles in cancer therapy
Zhi, D., Yang, T., Yang, J., Fu, S., & Zhang, S. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.11.027 · Cited by 283
Recent Advances of Chitosan Formulations in Biomedical Applications
Abourehab, M. A. S., Pramanik, S., Abdelgawad, M. A., Abualsoud, B. M., Kadi, A., Ansari, M. J., & Deepak, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810975 · Cited by 277
Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy
Fan, Y., & Moon, J. (2015) · Vaccines · doi:10.3390/vaccines3030662 · Cited by 275
Pearce, A. K., & O’Reilly, R. K. (2019) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00456 · Cited by 275
Emerging Concepts in Paracrine Mechanisms in Regenerative Cardiovascular Medicine and Biology
Hodgkinson, C. P., Bareja, A., Gomez, J. A., & Dzau, V. J. (2016) · Circulation Research · doi:10.1161/circresaha.115.305373 · Cited by 273
Lipid based nanocarriers: a translational perspective
Mishra, D. K., Shandilya, R., & Mishra, P. K. (2018) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2018.05.021 · Cited by 258
Single- versus Dual-Targeted Nanoparticles with Folic Acid and Biotin for Anticancer Drug Delivery
Jurczyk, M., Jelonek, K., Musiał-Kulik, M., Beberok, A., Wrześniok, D., & Kasperczyk, J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030326 · Cited by 133
Iron oxide-loaded nanotheranostics: major obstacles to in vivo studies and clinical translation
Schleich, N., Danhier, F., & Préat, V. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.11.024 · Cited by 124
“Furthermore, since PEGylation is a common technique improving nanocarriers stealth to avoid capture by the MPS, ligand grafting, by covering PEG corona, lowers the amount of available PEG and, thereby, alters pharmacokinetic and biodistribution profile [84].”
BackgroundAxial pharmaceutical properties of liposome in cancer therapy: Recent advances and perspectives
Kiaie, S. H., Mojarad-Jabali, S., Khaleseh, F., Allahyari, S., Taheri, E., Zakeri-Milani, P., & Valizadeh, H. (2020) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2020.119269 · Cited by 87
Amin, M., Mansourian, M., Koning, G. A., Badiee, A., Jaafari, M. R., & ten Hagen, T. L. M. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.039 · Cited by 83
Monitoring EPR Effect Dynamics during Nanotaxane Treatment with Theranostic Polymeric Micelles
Biancacci, I., De Lorenzi, F., Theek, B., Bai, X., May, J., Consolino, L., Baues, M., Moeckel, D., Gremse, F., von Stillfried, S., et al. (2022) · Advanced Science · doi:10.1002/advs.202103745 · Cited by 68
Biotin-decorated all-HPMA polymeric micelles for paclitaxel delivery
Wang, Y., van Steenbergen, M. J., Beztsinna, N., Shi, Y., Lammers, T., van Nostrum, C. F., & Hennink, W. E. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.09.013 · Cited by 66
EGF-liposomes promote efficient EGFR targeting in xenograft colocarcinoma model
Zalba, S., Contreras, A. M., Merino, M., Navarro, I., de Ilarduya, C. T., Trocóniz, I. F., Koning, G., & Garrido, M. J. (2016) · Nanomedicine · doi:10.2217/nnm.15.208 · Cited by 26
Metadata
- Authors
- van der Meel, R., Vehmeijer, L. J. C., Kok, R. J., Storm, G., & van Gaal, E. V. B.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2013-10
- Volume
- 65
- Issue
- 10
- Pages
- 1284-1298
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2129144690
- Cited by
- 398
- References
- 124
- FWCI
- 2.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.